Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.48 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.48 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.47 |
| ▸ | RELA | Q04206 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30408307 | 1.00 | HPGD (0.57) | HPGDSMN1; SMN2RAB9AALDH1A1EPHX2 | |
| SCHEMBL20627048 | 0.82 | RAB9A (0.50) | HPGDSMN1; SMN2RAB9AALDH1A1EPHX2 | |
| SCHEMBL13638725 | 0.81 | CPB1 (0.57) | HPGDSMN1; SMN2ALDH1A1EPHX2HSD17B10 | |
| SCHEMBL6813787 | 0.81 | CPB1 (0.57) | HPGDSMN1; SMN2ALDH1A1EPHX2HSD17B10 | |
| SCHEMBL6809188 | 0.81 | CPB1 (0.57) | HPGDSMN1; SMN2ALDH1A1EPHX2HSD17B10 | |
| SCHEMBL6521639 | 0.79 | ALDH1A1 (0.73) | RAB9AALDH1A1NFKB1NFKB2RELA | |
| SCHEMBL6521637 | 0.79 | ALDH1A1 (0.73) | RAB9AALDH1A1NFKB1NFKB2RELA | |
| SCHEMBL3705934 | 0.78 | HTT (0.63) | HPGDSMN1; SMN2RAB9AALDH1A1EPHX2 | |
| SCHEMBL23351144 | 0.78 | ALDH1A1 (0.57) | RAB9AALDH1A1MAPTNFKB1NFKB2 | |
| Hydrochloric Acid SCHEMBL11301487 | 0.77 | HTT (0.61) | HPGDSMN1; SMN2RAB9AALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| WO-2023069708-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | CRBN, GSPT1, GSPT2 | HPGD 2211/4885SMN1; SMN2 1830/4885RAB9A 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.